Intelligent Bio Solutions Inc Stock Price, News & Analysis

Intelligent Bio Solutions (NASDAQ: INBS) provided an update on its FDA clearance process for the Intelligent Fingerprint Drug Screening System, confirming its planned 2025 U.S. launch remains on track. The company submitted its 510(k) premarket notification on December 18, 2024, for its opiate test system, classified as a Class II device.

The submission included performance data showing 94.1% accuracy and Pharmacokinetic (PK) study results demonstrating fingerprint sweat's reliability for drug detection. The FDA has issued an Additional Information (AI) request, temporarily pausing the 90-day review period. While FDA clearance typically takes 3-6 months, the process may extend if additional data is required.

The system is currently operational in 19 countries with over 400 accounts globally. INBS plans to pursue FDA clearance for additional drug classes on its panel while preparing for entry into the U.S. market.

Intelligent Bio Solutions (INBS) announced the anticipated receipt of its sixth U.S. patent, strengthening protection for its lateral flow technology used in the Intelligent Fingerprinting Drug Testing Solution. The patent will safeguard the company's unique fingerprint sweat-based drug screening technology.

The expected patent grant comes as INBS advances its U.S. market entry strategy planned for 2025. The company's proprietary non-invasive drug testing technology addresses growing demand for workplace safety and compliance solutions. INBS has recently submitted an FDA 510(k) application and aims to expand its global market presence with this innovative sweat-based approach to drug screening.

Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company focused on intelligent, rapid, non-invasive testing solutions, has announced its participation in the upcoming iAccess Alpha Virtual Best Ideas Spring Conference 2025.

The conference is scheduled for March 25-26, 2025, with INBS management's presentation set for Tuesday, March 25th at 11:00 a.m. ET. The presentation will be accessible via webcast. Additionally, the company will conduct one-on-one meetings during the conference, which interested parties can schedule through iAccess representatives or by contacting KCSA Strategic Communications.

Intelligent Bio Solutions (Nasdaq: INBS) has completed its previously announced underwritten public offering, raising approximately $3.0 million in gross proceeds. The offering consisted of 1,500,000 shares of common stock priced at $2.00 per share, including the full exercise of the underwriter's option to purchase an additional 195,652 shares.

Ladenburg Thalmann & Co. Inc. served as the sole bookrunning manager for the offering, which was conducted under a shelf registration statement previously filed and declared effective by the SEC. The final prospectus supplement and accompanying prospectus are available on the SEC's website.

Intelligent Bio Solutions (Nasdaq: INBS) has announced the pricing of its public offering of 1,304,348 shares of common stock at $2.00 per share, aiming to raise approximately $2.6 million in gross proceeds before deducting underwriting costs and expenses.

Ladenburg Thalmann & Co. Inc. is serving as the sole bookrunning manager for the offering. The company has granted the underwriter a 45-day option to purchase up to an additional 195,652 shares at the public offering price less underwriting discounts. The offering is expected to close around February 21, 2025.

The net proceeds will be used for working capital and general corporate purposes. The offering is being made through a shelf registration statement filed with the SEC on April 8, 2022, and declared effective on April 20, 2022.

Intelligent Bio Solutions (Nasdaq: INBS), a medical technology company focused on rapid, non-invasive testing solutions, has announced plans for an underwritten public offering of common stock shares. The offering will be managed by Ladenburg Thalmann & Co. Inc. as the sole bookrunning manager.

The offering is being conducted under a shelf registration statement filed with the SEC on April 8, 2022, and declared effective on April 20, 2022. A preliminary prospectus supplement and accompanying prospectus will be filed with the SEC. The completion, size, and terms of the offering are subject to market conditions, with no guarantees of successful execution.

Intelligent Bio Solutions (NASDAQ: INBS) reported its fiscal Q2 2025 results, highlighting a 32.6% increase in gross profit and an 11-point rise in gross profit margin to 38.5%, driven by higher-margin cartridge sales. The company submitted its FDA 510(k) application in December 2024 and remains on track for U.S. market expansion in 2025.

Key financial metrics include Q2 revenue of $0.61 million, cash and equivalents of $2.24 million, and shareholders' equity of $4.20 million. The company secured 19 new accounts during the quarter, expanding its presence to over 400 active customers across 19 countries. However, revenue from sales decreased by $156,569 compared to the same quarter last year, and net loss increased to $2.25 million.

The company formed strategic partnerships with B2i Digital for investor marketing and Spirit Group for distribution in the Asia-Pacific region, while successfully completing method comparison and pharmacokinetic studies for its Intelligent Fingerprinting Drug Screening System.

Intelligent Bio Solutions (INBS) reported significant achievements in 2024 and outlined its 2025 U.S. expansion strategy. The company completed its FDA 510(k) pre-market notification in December 2024 for its Intelligent Fingerprinting Drug Testing Solution. Key financial highlights include 148% year-over-year revenue growth in fiscal 2024 and preliminary Q2 FY2024 revenue of $0.61 million, with improved gross profit margins reaching 38.5%.

The company currently serves over 400 accounts across 19 countries, reaching an estimated 1.4 million employees. Recent studies demonstrated approximately 94% accuracy in their drug testing system, with fingerprint sweat proving to be a reliable testing matrix. INBS is targeting the U.S. drug screening market, which represents 28% of the global market, with the total addressable market projected to reach $15 billion in the next six years.

Intelligent Bio Solutions (INBS) announces a new partnership with Avon Freight Group, implementing its fingerprint drug testing solution across three UK sites. This marks Avon's first in-house drug testing program, replacing their previous external oral swab testing method. INBS has expanded its presence to over 400 accounts across 19 countries.

The partnership highlights INBS's growth in the UK drug testing market, which is projected to reach $453 million by 2030. The company's non-invasive, rapid testing solution offers a more efficient and respectful alternative to traditional methods. Following its FDA 510(k) submission in December 2024, INBS is preparing for U.S. market expansion in 2025, positioning itself as a scalable, cost-effective leader in the drug testing industry.